Skip to content
PeptideGuideA closer look at the research
← All peptide reviews

Ghrelin-receptor research

Ipamorelin Research review

A human trial exists, but its surgical setting and negative efficacy result matter when assessing wellness claims.

01 / Context first

The research setting

Hospital patients recovering from bowel surgery received intravenous ipamorelin or placebo.

02 / The findings

What the sources found

  • The selected trial found no statistically significant improvement in its key or secondary efficacy analyses.

03 / The open questions

Where the evidence stops

  • This was a small postoperative study, not a test of muscle gain, sleep, or anti-aging.
  • Its findings do not establish benefits or safety for other routes or prolonged use.

04 / Safety context

Before drawing conclusions

FDA flags immune-response concerns and serious adverse events reported during intravenous use; other injection routes lack adequate safety information.

These reviews do not provide instructions for self-treatment. Discuss personal medical questions with a qualified clinician.

05 / Go to the originals

Read the sources

Inspect the original research and regulatory context behind this review.

  1. Original research — PubMed abstractProspective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. ↗
  2. FDA safety informationCertain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks ↗

Sources checked September 12, 2026. Next editorial review due December 11, 2026.

Read the review methodology →